Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. Marshall Edwards Inc (MEI) was incorporated in December 2000, but did not commence operations until May 2002, coinciding with its listing on the London Stock Exchange's Alternative Investment Market. The company, including an Australian subsidiary, Marshall Edwards Pty Limited (together the MEI Group), is a development-stage pharmaceutical company dedicated to the field of oncology. MEI is a subsidiary of the Australian pharmaceutical company, Novogen Limited, which held 86.9 per cent of MEI's issued capital as of 31st December 2003.